CA1270837A
(fr)
*
|
1984-12-21 |
1990-06-26 |
Hoffmann-La Roche Limited |
Oxetanones
|
CA1328881C
(fr)
*
|
1984-12-21 |
1994-04-26 |
Pierre Barbier |
Procede pour la fabrication d'oxetanones
|
ZA859574B
(en)
*
|
1984-12-21 |
1986-08-27 |
Hoffmann La Roche |
Process for the manufacture of oxetanones
|
JPH0618793Y2
(ja)
*
|
1986-06-13 |
1994-05-18 |
パイオニア株式会社 |
作業台
|
US4806564A
(en)
*
|
1987-05-26 |
1989-02-21 |
Merck & Co., Inc. |
Antihypercholesterolemic beta-lactones
|
US4816477A
(en)
*
|
1987-05-26 |
1989-03-28 |
Merck & Co., Inc. |
Antihypercholesterolemic β-lactones
|
US5063210A
(en)
*
|
1989-04-20 |
1991-11-05 |
Lange Iii Louis G |
Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
|
US5484777A
(en)
*
|
1989-04-20 |
1996-01-16 |
Lange, Iii; Louis G. |
Pancreatic cholesterol esterase inhibitor
|
US5017565A
(en)
*
|
1989-04-20 |
1991-05-21 |
Lange Iii Louis G |
Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
|
JP2960947B2
(ja)
*
|
1989-12-25 |
1999-10-12 |
日清製粉株式会社 |
脂質分解酵素阻害剤
|
US5376640A
(en)
*
|
1989-12-25 |
1994-12-27 |
Nisshin Flour Milling Co., Ltd. |
Lipolytic enzyme inhibitors
|
CA2098167C
(fr)
*
|
1992-06-24 |
2006-12-19 |
Dorothea Isler |
Aliments pour humains et animaux contenant un inhibiteur de la lipase
|
TW381025B
(en)
*
|
1993-08-05 |
2000-02-01 |
Hoffmann La Roche |
Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
MY116591A
(en)
*
|
1996-04-26 |
2004-02-28 |
Hoffmann La Roche |
Process for the production of lipstatin and tetrahydrolipstatin
|
US6004996A
(en)
*
|
1997-02-05 |
1999-12-21 |
Hoffman-La Roche Inc. |
Tetrahydrolipstatin containing compositions
|
DK1017408T3
(da)
*
|
1997-02-05 |
2005-08-01 |
Hoffmann La Roche |
Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
|
US7344713B1
(en)
*
|
1997-07-07 |
2008-03-18 |
Pimentel Julio L |
Decreased fat absorption with an anti-lipase antibody
|
GB9727131D0
(en)
*
|
1997-12-24 |
1998-02-25 |
Knoll Ag |
Therapeutic agents
|
US6264937B1
(en)
|
1998-01-09 |
2001-07-24 |
Geltex Pharmaceuticals, Inc. |
Fat-binding polymers
|
US7048917B1
(en)
|
1998-01-09 |
2006-05-23 |
Genzyme Corporation |
Fat-binding polymers
|
US6299868B1
(en)
|
1999-07-14 |
2001-10-09 |
Geltex Pharmaceuticals, Inc. |
Fat-binding polymers
|
DK1105122T3
(da)
|
1998-08-14 |
2005-08-08 |
Hoffmann La Roche |
Pharmaceutical compositions containing lipase inhibitors
|
ES2217797T3
(es)
*
|
1998-08-14 |
2004-11-01 |
F. Hoffmann-La Roche Ag |
Vinileteres heterociclicos contra trastornos neurologicos.
|
ES2201827T3
(es)
|
1998-12-23 |
2004-03-16 |
G.D. Searle Llc |
Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de derivados de acido fibrico para indicaciones cardiovasculares.
|
DK1140190T3
(da)
|
1998-12-23 |
2002-12-23 |
Searle Llc |
Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
|
US6462091B1
(en)
|
1998-12-23 |
2002-10-08 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
|
PT1140185E
(pt)
|
1998-12-23 |
2003-10-31 |
Searle Llc |
Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com agentes sequestrantes de acido biliar para indicacoes cardiovasculares
|
WO2000038726A1
(fr)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
|
CZ20012342A3
(cs)
|
1998-12-23 |
2001-12-12 |
G. D. Searle Llc |
Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny fibrové pro kardiovaskulární indikace
|
EP1140184B1
(fr)
|
1998-12-23 |
2003-06-04 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
|
ES2185523T3
(es)
*
|
1999-01-29 |
2003-05-01 |
Hoffmann La Roche |
Purificacion de lipstatina.
|
WO2001005408A1
(fr)
*
|
1999-07-14 |
2001-01-25 |
Geltex Pharmaceuticals, Inc. |
Polymeres fixant la graisse, combines eventuellement avec des inhibiteurs de lipase
|
AR025609A1
(es)
|
1999-09-13 |
2002-12-04 |
Hoffmann La Roche |
Formulaciones lipidas solidas
|
AR025587A1
(es)
*
|
1999-09-13 |
2002-12-04 |
Hoffmann La Roche |
Formulaciones en dispersion que contienen inhibidores de lipasa
|
EP1132389A1
(fr)
|
2000-03-06 |
2001-09-12 |
Vernalis Research Limited |
Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
DE10021618A1
(de)
*
|
2000-05-04 |
2001-11-15 |
Volker Helmstaedter |
Präparat für Darmerkrankungen und dessen Verwendung
|
EP1142572A1
(fr)
*
|
2000-04-04 |
2001-10-10 |
Volker Dr. Helmstädter |
Composés contenant de l'oxetanon destinés au traitement des maladies intestinales
|
EP1296656B1
(fr)
|
2000-06-27 |
2006-08-02 |
F. Hoffmann-La Roche Ag |
Procede de preparation de composition
|
SI1307264T1
(en)
|
2000-07-28 |
2005-02-28 |
F. Hoffmann-La Roche Ag |
New pharmaceutical composition
|
EP1307263B1
(fr)
|
2000-07-28 |
2005-04-20 |
F. Hoffmann-La Roche Ag |
Nouvelle application d'inhibiteurs de lipase
|
PT1311260E
(pt)
*
|
2000-08-09 |
2008-05-02 |
Hoffmann La Roche |
Utilização de inibidores de lipase para o tratamento da dispepsia
|
US6900226B2
(en)
|
2000-09-06 |
2005-05-31 |
Hoffman-La Roche Inc. |
Neuropeptide Y antagonists
|
JP4047723B2
(ja)
|
2000-10-16 |
2008-02-13 |
エフ.ホフマン−ラ ロシュ アーゲー |
インドリン誘導体、および5−ht2受容体リガンドとしてのその使用
|
GB0030710D0
(en)
*
|
2000-12-15 |
2001-01-31 |
Hoffmann La Roche |
Piperazine derivatives
|
MXPA03005915A
(es)
|
2000-12-27 |
2003-09-10 |
Hoffmann La Roche |
Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.
|
GB0106177D0
(en)
*
|
2001-03-13 |
2001-05-02 |
Hoffmann La Roche |
Piperazine derivatives
|
US20030091610A1
(en)
*
|
2001-03-19 |
2003-05-15 |
The Procter & Gamble Company |
Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
|
US20030072804A1
(en)
*
|
2001-03-19 |
2003-04-17 |
The Procter & Gamble Company |
Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
|
KR100621287B1
(ko)
*
|
2001-05-21 |
2006-09-13 |
에프. 호프만-라 로슈 아게 |
신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체
|
US6730319B2
(en)
|
2001-06-06 |
2004-05-04 |
Hoffmann-La Roche Inc. |
Pharmaceutical compositions having depressed melting points
|
US20030027786A1
(en)
|
2001-06-06 |
2003-02-06 |
Karsten Maeder |
Lipase inhibiting composition
|
US7041280B2
(en)
*
|
2001-06-29 |
2006-05-09 |
Genzyme Corporation |
Aryl boronate functionalized polymers for treating obesity
|
US7049345B2
(en)
|
2001-06-29 |
2006-05-23 |
Genzyme Corporation |
Fat-binding polymers
|
DE60232170D1
(de)
*
|
2001-08-30 |
2009-06-10 |
Alizyme Therapeutics Ltd |
Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung
|
US6787558B2
(en)
*
|
2001-09-28 |
2004-09-07 |
Hoffmann-La Roche Inc. |
Quinoline derivatives
|
US20070281003A1
(en)
|
2001-10-12 |
2007-12-06 |
Fuisz Richard C |
Polymer-Based Films and Drug Delivery Systems Made Therefrom
|
US20190328679A1
(en)
|
2001-10-12 |
2019-10-31 |
Aquestive Therapeutics, Inc. |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US8900497B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for making a film having a substantially uniform distribution of components
|
US11207805B2
(en)
|
2001-10-12 |
2021-12-28 |
Aquestive Therapeutics, Inc. |
Process for manufacturing a resulting pharmaceutical film
|
US8603514B2
(en)
|
2002-04-11 |
2013-12-10 |
Monosol Rx, Llc |
Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
|
US7357891B2
(en)
|
2001-10-12 |
2008-04-15 |
Monosol Rx, Llc |
Process for making an ingestible film
|
US20110033542A1
(en)
|
2009-08-07 |
2011-02-10 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
US8765167B2
(en)
|
2001-10-12 |
2014-07-01 |
Monosol Rx, Llc |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US8900498B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for manufacturing a resulting multi-layer pharmaceutical film
|
US10285910B2
(en)
|
2001-10-12 |
2019-05-14 |
Aquestive Therapeutics, Inc. |
Sublingual and buccal film compositions
|
GB0125659D0
(en)
*
|
2001-10-25 |
2001-12-19 |
Ssl Int Plc |
Spermicides
|
WO2003040127A1
(fr)
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Composes benzothiepine mono- et di-fluores en tant qu'inhibiteurs du transport d'acides biliaires a co-dependance sodique apicale (asbt) et de reprise de taurocholate
|
US6844174B2
(en)
|
2001-12-04 |
2005-01-18 |
Biogal Gyogyszergyar Rt. |
Fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
|
IL162323A0
(en)
*
|
2001-12-04 |
2005-11-20 |
Biogal Pharmaceutical Co |
Preparation of orlistat and orlistat crystalline forms
|
CN1620439A
(zh)
|
2001-12-20 |
2005-05-25 |
Osi药物公司 |
胰脂肪酶抑制剂化合物、其合成方法和应用
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
GB0202015D0
(en)
*
|
2002-01-29 |
2002-03-13 |
Hoffmann La Roche |
Piperazine Derivatives
|
DE60320529T2
(de)
*
|
2002-02-04 |
2009-06-10 |
F. Hoffmann-La Roche Ag |
Chinolinderivate als npy antagonisten
|
AU2003210305B2
(en)
*
|
2002-02-28 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Thiazole derivatives as NPY receptor antagonists
|
US7728153B2
(en)
|
2002-04-17 |
2010-06-01 |
The Burnham Institute For Medical Research |
Method for the asymmetric synthesis of beta-lactone compounds
|
AU2003226370A1
(en)
*
|
2002-04-17 |
2003-11-03 |
The Burnham Institute |
Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
|
DE60330764D1
(de)
*
|
2002-04-26 |
2010-02-11 |
Hoffmann La Roche |
Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
CA2489251A1
(fr)
*
|
2002-07-05 |
2004-01-15 |
F. Hoffmann-La Roche Ag |
Derives de quinazoline
|
CA2493712A1
(fr)
*
|
2002-08-07 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
Derives d'aminothiazole pouvant servir d'inhibiteurs de recepteur npy5
|
KR100645684B1
(ko)
*
|
2002-09-12 |
2006-11-15 |
에프. 호프만-라 로슈 아게 |
당뇨병 치료에 유용한 ppar 작동제로서 n-치환된-1h-인돌-5-프로파이온산 화합물
|
JP4384052B2
(ja)
*
|
2002-11-25 |
2009-12-16 |
エフ.ホフマン−ラ ロシュ アーゲー |
インドリル誘導体
|
US8372430B2
(en)
|
2002-12-17 |
2013-02-12 |
The Procter & Gamble Company |
Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20040178058A1
(en)
*
|
2003-03-10 |
2004-09-16 |
Hsueh-Chung Chen |
Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
|
EP1457206A1
(fr)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
|
WO2004106299A2
(fr)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Derives pyrroliques substitues
|
WO2004113314A1
(fr)
*
|
2003-06-23 |
2004-12-29 |
Biocon Limited |
Nouveaux esters de boronate
|
GB0314967D0
(en)
*
|
2003-06-26 |
2003-07-30 |
Hoffmann La Roche |
Piperazine derivatives
|
US20060025337A1
(en)
*
|
2003-07-01 |
2006-02-02 |
President And Fellows Of Harvard College |
Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
|
WO2005007639A1
(fr)
*
|
2003-07-17 |
2005-01-27 |
Biocon Limited |
Preparation de tetrahydrolipstatine par hydrogenation de lipstatine, extraction par solvant et purification
|
ATE380189T1
(de)
*
|
2003-08-12 |
2007-12-15 |
Hoffmann La Roche |
2-amino-5-benzoylthiazol npy-antagonisten
|
WO2005014593A1
(fr)
*
|
2003-08-12 |
2005-02-17 |
F. Hoffmann-La Roche Ag |
Derives de thiazole utiles comme antagonistes de npy *
|
US20050239859A2
(en)
*
|
2003-09-03 |
2005-10-27 |
Solvay Pharmaceuticals Gmbh |
Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
|
US7547693B2
(en)
|
2003-09-22 |
2009-06-16 |
Banyu Pharmaceutical Co. Ltd. |
Piperidine derivative
|
US20050143441A1
(en)
*
|
2003-10-27 |
2005-06-30 |
Jochen Antel |
Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
US20050124660A1
(en)
*
|
2003-10-27 |
2005-06-09 |
Jochen Antel |
Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
|
EP2428516A1
(fr)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Nouvelles substances thyromimetiques contenant du phosphore
|
US8017634B2
(en)
|
2003-12-29 |
2011-09-13 |
President And Fellows Of Harvard College |
Compositions for treating obesity and insulin resistance disorders
|
JP2007527418A
(ja)
*
|
2003-12-29 |
2007-09-27 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
肥満及びインシュリン耐性障害を治療又は防止するための組成物
|
PL209905B1
(pl)
*
|
2004-01-15 |
2011-11-30 |
Bringwell Internat Ab |
Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
|
KR20060124679A
(ko)
|
2004-01-16 |
2006-12-05 |
후지 세이유 가부시키가이샤 |
리파아제 저해제
|
US7074822B2
(en)
|
2004-02-23 |
2006-07-11 |
Solvay Pharmaceuticals Gmbh |
Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
AU2005239788A1
(en)
|
2004-05-10 |
2005-11-17 |
University Of Copenhagen |
Flaxseeds for body weight management
|
US7879866B2
(en)
*
|
2004-07-19 |
2011-02-01 |
Dorte Xenia Gram |
Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
|
MX2007004889A
(es)
|
2004-10-25 |
2007-09-11 |
Solvay Pharm Gmbh |
Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
|
ATE439347T1
(de)
*
|
2004-11-23 |
2009-08-15 |
Warner Lambert Co |
7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
|
WO2006110809A2
(fr)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International, Limited |
Formulations inhibitrices de lipase nanoparticulaire
|
ATE514698T1
(de)
*
|
2005-05-03 |
2011-07-15 |
Hoffmann La Roche |
Tetracyclische azapyrazinoindoline als 5-ht2- liganden
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
WO2006138418A2
(fr)
*
|
2005-06-14 |
2006-12-28 |
President And Fellows Of Harvard College |
Amelioration de la performance cognitive avec des activateurs de sirtuine
|
US20070149466A1
(en)
*
|
2005-07-07 |
2007-06-28 |
Michael Milburn |
Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
|
WO2007018248A1
(fr)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
Composé de pyridone
|
CA2618568A1
(fr)
*
|
2005-08-18 |
2007-02-22 |
F. Hoffmann-La Roche Ag |
Derives de thiazolylpiperidines
|
WO2007024004A1
(fr)
|
2005-08-24 |
2007-03-01 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé phénylpyridone
|
JPWO2007029847A1
(ja)
|
2005-09-07 |
2009-03-19 |
萬有製薬株式会社 |
二環性芳香族置換ピリドン誘導体
|
US7355055B2
(en)
*
|
2005-09-08 |
2008-04-08 |
Reliance Life Sciences Pvt. Ltd. |
Compounds for treatment of lipase-mediated diseases
|
WO2007048027A2
(fr)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combinaison de composes organiques
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US8163770B2
(en)
|
2005-10-27 |
2012-04-24 |
Msd. K. K. |
Benzoxathiin derivative
|
KR101329112B1
(ko)
*
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
WO2007055418A1
(fr)
|
2005-11-10 |
2007-05-18 |
Banyu Pharmaceutical Co., Ltd. |
Derive spiro aza-substitue
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
AU2006319232B2
(en)
*
|
2005-11-30 |
2012-09-13 |
F. Hoffmann-La Roche Ag |
1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators
|
BRPI0619233A2
(pt)
*
|
2005-11-30 |
2011-09-20 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
|
EP1957479B1
(fr)
*
|
2005-11-30 |
2011-03-02 |
F. Hoffmann-La Roche AG |
Derives de indole-2-yl amide substitues en 1,5
|
ATE448230T1
(de)
*
|
2005-12-09 |
2009-11-15 |
Hoffmann La Roche |
Für die behandlung von obesitas geeignete tricyclische amidderivate
|
JP2009519290A
(ja)
*
|
2005-12-15 |
2009-05-14 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピロロ[2,3−c]ピリジン誘導体
|
KR101015666B1
(ko)
*
|
2005-12-16 |
2011-02-22 |
에프. 호프만-라 로슈 아게 |
H3 수용체 조절제로서 피롤로[2,3-b]피리딘 유도체
|
SK22006A3
(sk)
*
|
2006-01-03 |
2007-08-02 |
Biotika, A. S. |
Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
|
US20080021092A1
(en)
*
|
2006-01-06 |
2008-01-24 |
Deepak Murpani |
Stable pharmaceutical compositions of orlistat
|
WO2007080140A1
(fr)
*
|
2006-01-13 |
2007-07-19 |
F. Hoffmann-La Roche Ag |
Dérivés de méthanone de type cyclohexyle et pipérazinyle et leur application en tant que modulateurs du récepteur h3 de l'histamine
|
CA2637449A1
(fr)
*
|
2006-01-23 |
2007-07-26 |
F. Hoffmann-La Roche Ag |
Derives de cyclohexylsulfonamide presentant une activite vis-a-vis des recepteurs h3
|
WO2008020314A2
(fr)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Formulations de dosage stabilisantes à base de statine
|
KR101252635B1
(ko)
|
2006-04-20 |
2013-04-10 |
(주)아모레퍼시픽 |
리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
|
US7432255B2
(en)
*
|
2006-05-16 |
2008-10-07 |
Hoffmann-La Roche Inc. |
1H-indol-5-yl-piperazin-1-yl-methanone derivatives
|
JP2009538859A
(ja)
*
|
2006-05-30 |
2009-11-12 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピペリジニルピリミジン誘導体
|
MX2009000439A
(es)
*
|
2006-07-14 |
2009-02-04 |
Ranbaxy Lab Ltd |
Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
|
US7514433B2
(en)
|
2006-08-03 |
2009-04-07 |
Hoffmann-La Roche Inc. |
1H-indole-6-yl-piperazin-1-yl-methanone derivatives
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
WO2008045564A2
(fr)
*
|
2006-10-12 |
2008-04-17 |
Epix Delaware, Inc. |
Composés de carboxamide et leur utilisation
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
US20080146559A1
(en)
|
2006-12-08 |
2008-06-19 |
Li Chen |
4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
|
US20080200422A1
(en)
*
|
2007-01-09 |
2008-08-21 |
Cavener Douglas R |
Methods for reduction of adipose tissue mass
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
WO2008124120A1
(fr)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinaisons de statines et d'agent anti-obésité
|
WO2008124122A1
(fr)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinaisons de statines, d'agent anti-obésité et de glitazones
|
EP2581081A3
(fr)
*
|
2007-06-01 |
2013-07-31 |
The Trustees Of Princeton University |
Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2008149321A2
(fr)
*
|
2007-06-06 |
2008-12-11 |
Ranbaxy Laboratories Limited |
Procédé perfectionné pour la préparation d'orlistat
|
US9066536B2
(en)
|
2007-09-12 |
2015-06-30 |
University Of Copenhagen |
Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
|
US20100196464A1
(en)
*
|
2007-09-17 |
2010-08-05 |
Dr. Reddy's Laboratories Limited |
Orlistat pharmaceutical formulations
|
WO2009044380A2
(fr)
|
2007-10-05 |
2009-04-09 |
Ranbaxy Laboratories Limited |
Formulations contenant des particules d'orlistat à dimension de particule contrôlée
|
EP2219614A1
(fr)
*
|
2007-10-15 |
2010-08-25 |
Inventis DDS Pvt Limited |
Composition pharmaceutique d'orlistat
|
US8298583B2
(en)
*
|
2007-10-19 |
2012-10-30 |
Monosol Rx, Llc |
Film delivery system for tetrahydrolipstatin
|
RU2010128543A
(ru)
|
2007-12-11 |
2012-01-20 |
Сайтопатфайндер, Инк. (Jp) |
Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
|
US20090214682A1
(en)
*
|
2008-02-22 |
2009-08-27 |
Heuer Marvin A |
Composition and methods for weight loss in a subject
|
JPWO2009110510A1
(ja)
|
2008-03-06 |
2011-07-14 |
Msd株式会社 |
アルキルアミノピリジン誘導体
|
ES2755736T3
(es)
*
|
2008-03-26 |
2020-04-23 |
Biocon Ltd |
Proceso de fermentación mejorado para un coeficiente de rendimiento más alto de inhibidor de lipasa respecto al ácido graso consumido
|
CN101981025A
(zh)
|
2008-03-28 |
2011-02-23 |
万有制药株式会社 |
具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
AU2009261248A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
EP2141236A1
(fr)
*
|
2008-07-03 |
2010-01-06 |
KRKA, D.D., Novo Mesto |
Procédé de production de lipstatine et microorganismes correspondant
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
WO2010013595A1
(fr)
|
2008-07-30 |
2010-02-04 |
萬有製薬株式会社 |
Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons)
|
CN102170798B
(zh)
|
2008-10-03 |
2013-06-12 |
西格马食品可变资本有限公司 |
用于促进对总胆固醇和ldl胆固醇的控制和/或体重减轻和/或生热作用的组合物
|
WO2010042499A1
(fr)
*
|
2008-10-06 |
2010-04-15 |
Banner Pharmacaps, Inc. |
Solutions stables d'orlistat pour formes galéniques pharmaceutiques
|
WO2010043592A1
(fr)
*
|
2008-10-15 |
2010-04-22 |
Revotar Biopharmaceuticals Ag |
Inhibiteurs de la lipase destinés à être utilisés dans le traitement de l’obésité
|
MX2011004258A
(es)
|
2008-10-22 |
2011-06-01 |
Merck Sharp & Dohme |
Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
|
CA2741672A1
(fr)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
|
WO2010093601A1
(fr)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
|
EP2395987A1
(fr)
|
2009-02-12 |
2011-12-21 |
Coöperatieve Mirzorg U.A., Arnhem |
Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
|
US20100215635A1
(en)
*
|
2009-02-23 |
2010-08-26 |
Zoltan Kiss |
Small molecules to induce weight loss or to reduce weight gain
|
EP2414830A2
(fr)
|
2009-03-31 |
2012-02-08 |
Robert Zimmermann |
Modulation de l'adipose triglycéride lipase pour prévenir et traiter la cachexie, la perte de poids et l'atrophie musculaire et procédés de criblage à des fins d'identification
|
WO2010112569A1
(fr)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation de lipase de triglycérides d'adipose pour la prévention et le traitement d'une cachexie, d'une perte de poids et d'une atrophie musculaire et procédés de criblage s'y rapportant
|
BRPI0901602B8
(pt)
|
2009-04-03 |
2021-05-25 |
Ems S/A |
formulação farmacêuticas
|
US9334266B2
(en)
|
2009-09-04 |
2016-05-10 |
The University Of Toledo |
Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
|
ME02016B
(me)
|
2009-11-02 |
2015-05-20 |
Pfizer |
Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
|
UA107369C2
(en)
|
2010-02-01 |
2014-12-25 |
Lab Bago S A |
Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
|
US8524909B2
(en)
|
2010-02-02 |
2013-09-03 |
Hoffmann-La Roche Inc. |
Tetrahydro-pyran derivatives
|
CA2786314A1
(fr)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques
|
WO2011140296A1
(fr)
|
2010-05-05 |
2011-11-10 |
Infinity Pharmaceuticals |
Triazoles utilisés comme inhibiteurs d'acides gras synthase (fasn)
|
EP2566853B1
(fr)
|
2010-05-05 |
2017-01-25 |
Infinity Pharmaceuticals, Inc. |
Tétrazolones utilisés en tant qu'inhibiteurs d'acide gras synthase (fasn)
|
WO2011145022A1
(fr)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phénylbenzoylamides
|
US9237762B2
(en)
|
2010-05-24 |
2016-01-19 |
Swedish Oat Fiber Ab |
Aqueous dispersion comprising galactolipids and method for production thereof
|
EP2392327A1
(fr)
|
2010-06-04 |
2011-12-07 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Utilisation d'orlistat pour le traitement antiparasite d'une maladie de parasite
|
EP2590969B1
(fr)
|
2010-07-06 |
2014-10-15 |
AstraZeneca AB |
Agents thérapeutiques 976
|
CN101885713B
(zh)
*
|
2010-07-19 |
2011-11-30 |
大邦(湖南)生物制药有限公司 |
一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CN101948450B
(zh)
*
|
2010-10-13 |
2013-04-24 |
鲁南制药集团股份有限公司 |
一种生产制备奥利司他的方法
|
US9149959B2
(en)
|
2010-10-22 |
2015-10-06 |
Monosol Rx, Llc |
Manufacturing of small film strips
|
CN103228270B
(zh)
|
2010-11-08 |
2016-02-10 |
阿尔比里奥公司 |
含ibat抑制剂和胆汁酸结合剂的药物组合
|
RU2591188C2
(ru)
|
2010-11-08 |
2016-07-10 |
Альбирео Аб |
Ингибиторы ibat для лечения заболеваний печени
|
KR101668514B1
(ko)
|
2011-02-25 |
2016-10-21 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
|
EP2680874A2
(fr)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Peptides de type edn3 et utilisations associées
|
UY34194A
(es)
|
2011-07-15 |
2013-02-28 |
Astrazeneca Ab |
?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
|
CN102304105B
(zh)
*
|
2011-07-15 |
2013-07-10 |
鲁南新时代生物技术有限公司 |
一种制备高纯度奥利司他的方法
|
CN103030613B
(zh)
*
|
2011-09-29 |
2014-11-12 |
北大方正集团有限公司 |
一种利普司他汀的提纯方法
|
JP2013249293A
(ja)
*
|
2012-06-04 |
2013-12-12 |
Kao Corp |
リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
|
JP2015525782A
(ja)
|
2012-08-02 |
2015-09-07 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病性三環式化合物
|
WO2014060445A1
(fr)
|
2012-10-19 |
2014-04-24 |
Akzo Nobel Chemicals International B.V. |
Procédé de préparation d'orlistat à haut degré de pureté
|
CN102936234B
(zh)
*
|
2012-11-15 |
2015-04-01 |
江苏阿尔法药业有限公司 |
一种制备脂肪酶抑制剂奥利司他的方法
|
CN102993134B
(zh)
*
|
2012-12-31 |
2015-08-05 |
鲁南新时代生物技术有限公司 |
一种利普司他汀的提纯方法
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
WO2014170786A1
(fr)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015051496A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Composés tricycliques antidiabétiques
|
MX2017002610A
(es)
|
2014-08-29 |
2017-10-11 |
Tes Pharma S R L |
INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
|
US10743813B2
(en)
|
2014-09-11 |
2020-08-18 |
Rattan Nath |
Diabetes control using postprandial feedback
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
US11273131B2
(en)
|
2016-05-05 |
2022-03-15 |
Aquestive Therapeutics, Inc. |
Pharmaceutical compositions with enhanced permeation
|
CN109310646A
(zh)
|
2016-05-05 |
2019-02-05 |
阿奎斯蒂弗医疗股份有限公司 |
增强递送的肾上腺素组合物
|
US20180134667A1
(en)
|
2016-10-14 |
2018-05-17 |
TES Pharma S.r.I. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
WO2018106518A1
(fr)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques antidiabétiques
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
MX2021005904A
(es)
|
2018-11-20 |
2021-09-08 |
Tes Pharma S R L |
Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
|
CN113574055A
(zh)
|
2019-01-18 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
NL2022615B1
(en)
|
2019-02-21 |
2020-08-31 |
Patrick Alexander Unger |
Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
|
EP4101467A4
(fr)
|
2020-02-05 |
2024-03-06 |
NOF Corporation |
Agent pour traiter ou prévenir une fistule pancréatique
|